Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.42 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -44%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.27 per share when it actually produced a loss of $0.26, delivering a surprise of 3.70%.Over the last four quarters, the c ...

Financial Performance - The company has not generated any revenue from product sales and does not expect to do so in the near future[89]. - The company incurred net losses of $40.5 million and $36.1 million for the three months ended March 31, 2025 and 2024, respectively, with an accumulated deficit of $869.6 million as of March 31, 2025[89]. - Collaboration revenue decreased to $3.7 million for the three months ended March 31, 2025, down from $15.9 million in the same period of 2024, a decline of $12.2 million[105]. - The net loss for the three months ended March 31, 2025, was $40.5 million, compared to a net loss of $36.1 million in the same period of 2024[104]. - Total operating expenses for the three months ended March 31, 2025, were $48.4 million, a decrease of $11.2 million from $59.6 million in 2024[104]. - Research and development expenses were $33.6 million for the three months ended March 31, 2025, down from $45.2 million in 2024, reflecting a decrease of $11.5 million[106]. Cash and Liquidity - As of March 31, 2025, the company had $354.6 million in cash, cash equivalents, and marketable securities, with an accumulated deficit of $869.6 million[111]. - Cash used in operating activities was $60.8 million for the three months ended March 31, 2025, compared to $61.3 million in 2024[116]. - The company expects to fund operations into the second half of 2027 based on current cash reserves and operational plans[113]. - Cash provided by investing activities was $65.7 million for the three months ended March 31, 2025, primarily from maturities of marketable securities[119]. - The company entered into an at-the-market sales agreement to offer up to $125 million of common stock[113]. - As of March 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $354.6 million, primarily in money market funds, U.S. treasury and agency securities, corporate bonds, certificates of deposit, and commercial paper[127]. - Approximately $0.3 million of cash and cash equivalents exceeded the FDIC insurance limit of $250,000 as of March 31, 2025[128]. - The majority of the company's operating cash is held at JPMorgan Chase & Co.[128]. Clinical Development - The company is advancing its clinical pipeline with latozinemab (AL001) in a pivotal Phase 3 trial and AL101/GSK4527226 in a Phase 2 trial, with enrollment for both trials completed[80][83]. - Latozinemab is being developed for frontotemporal dementia (FTD-GRN), affecting approximately 50,000 to 60,000 people in the U.S. and 110,000 in the EU, with no approved therapies currently available[79]. - The company expects research and development expenses to increase substantially as product candidates advance into later stages of development and larger clinical trials are conducted[99]. Strategic Initiatives - The company plans to reduce its workforce by approximately 13%, impacting about 25 employees, to align resources with strategic priorities[90]. - The company has a proprietary technology platform, Alector Brain Carrier (ABC), aimed at enhancing the delivery of therapeutics across the blood-brain barrier[75]. - The company aims to develop biomarkers to improve the probability of technical success and shorten development timelines for its product candidates[76]. Financial Risks - An immediate 100 basis point increase or decrease in interest rates would result in a fair value change of approximately $1.3 million[127]. - The company has limited exposure to foreign currency risk, with expenses generally denominated in U.S. dollars[129]. - Foreign currency transaction gains and losses have not been material to the company's financial statements[129]. - A 10% increase or decrease in current exchange rates would not have a material effect on the company's financial results[129]. Deferred Revenue - The deferred revenue balance was $192.2 million as of March 31, 2025, related to the GSK Agreement, expected to be recognized over the research and development period[94]. - The company received $700 million in upfront payments under the GSK Agreement, with the potential to earn up to an additional $1.5 billion in milestone payments for product candidates[92].

Financial Performance - Collaboration revenue for Q1 2025 was $3.7 million, a decrease of 77.8% compared to $15.9 million in Q1 2024[10] - Alector reported a net loss of $40.5 million, or $0.41 per share, compared to a net loss of $36.1 million, or $0.38 per share, for the same period in 2024[13] - Total general and administrative expenses for Q1 2025 were $14.7 million, slightly up from $14.4 million in Q1 2024[12] - Management anticipates collaboration revenue for 2025 to be between $5 million and $15 million[14] Research and Development - Total research and development expenses for Q1 2025 were $33.6 million, down 25.6% from $45.2 million in Q1 2024[11] - The pivotal INFRONT-3 Phase 3 trial of latozinemab is on track to report topline data in Q4 2025[3] - Enrollment in the PROGRESS-AD Phase 2 trial of AL101 was completed ahead of schedule in April 2025[7] - Alector continues to advance its preclinical and early research pipeline, including brain-penetrant therapies for neurodegenerative diseases[8] Financial Position - Cash, cash equivalents, and investments totaled $354.6 million as of March 31, 2025, sufficient to fund operations into the second half of 2027[13] - Total liabilities as of March 31, 2025, were $313.7 million, down from $341.5 million at the end of 2024[19]

Core Insights - Alector, Inc. is advancing its clinical pipeline for neurodegenerative diseases, with key trials expected to report results in late 2025 [1][2][5] - The company has extended its cash runway into the second half of 2027, with a total of $354.6 million in cash, cash equivalents, and investments as of March 31, 2025 [1][12] Clinical Developments - The pivotal INFRONT-3 Phase 3 trial of latozinemab for frontotemporal dementia with a granulin gene mutation is on track to report topline data in Q4 2025 [2][5] - Enrollment in the PROGRESS-AD Phase 2 trial of AL101/GSK4527226 for early Alzheimer's disease has been completed ahead of schedule [4][6] - Alector is pursuing its Alector Brain Carrier programs, which include an anti-amyloid beta antibody and GCase enzyme replacement therapy, both targeting validated genetic pathways [2][7] Financial Performance - Collaboration revenue for Q1 2025 was $3.7 million, a decrease from $15.9 million in Q1 2024, primarily due to the completion of obligations related to previous programs [9] - Total R&D expenses for Q1 2025 were $33.6 million, down from $45.2 million in the same quarter of 2024, reflecting cost management efforts [10] - The net loss for Q1 2025 was $40.5 million, or $0.41 per share, compared to a net loss of $36.1 million, or $0.38 per share, in Q1 2024 [11][20] Corporate Updates - Giacomo Salvadore, M.D., has been appointed as Chief Medical Officer, bringing over 15 years of experience in neurology-focused clinical development [8] - Alector continues to leverage its proprietary blood-brain barrier technology platform, Alector Brain Carrier, to enhance therapeutic delivery to the brain [7][15]

Financial Data and Key Metrics Changes - As of December 31, 2024, the company's cash, cash equivalents, and short-term investments totaled $413.4 million [36] - Collaboration revenue for Q4 2024 was $54.2 million, up from $15.2 million in Q4 2023, while total collaboration revenue for the year was $100.6 million compared to $97.1 million in 2023 [37] - Total research and development expenses for Q4 2024 were $46.5 million, down from $47.7 million in Q4 2023, and for the year, they were $185.9 million compared to $192.1 million in 2023 [38] - Total general and administrative expenses for Q4 2024 were $15 million, slightly up from $14.9 million in Q4 2023, and for the year, they were $59.6 million compared to $56.7 million in 2023 [38] Business Line Data and Key Metrics Changes - The company is advancing two first-in-class late-stage clinical programs developed in collaboration with GSK, focusing on neurodegenerative disorders [9] - The pivotal Phase 3 trial in frontotemporal dementia with progranulin gene mutation is expected to read out later this year [10] - The ongoing PROGRESS-AD Phase 2 trial of AL101 in early Alzheimer's disease is expected to complete patient recruitment by early 2025 [10] Market Data and Key Metrics Changes - The company is targeting high unmet medical needs in neurodegenerative disorders such as frontotemporal dementia, Alzheimer's disease, and Parkinson's disease [7] - The company anticipates realizing a significant portion of its potential in 2025, with a focus on data-driven decisions to create sustainable value [10] Company Strategy and Development Direction - The company aims to discover and develop first or best-in-class disease-modifying therapies for neurodegenerative disorders [7] - The proprietary Alector Brain Carrier (ABC) platform is central to the company's strategy, enhancing the delivery of therapeutics to the brain [9] - The company is committed to advancing its preclinical pipeline, including programs targeting amyloid beta and tau pathology [33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential for Latozinemab to provide a path to full approval based on the totality of evidence, including primary clinical endpoints and biomarkers [20][99] - The company remains optimistic about the upcoming readout of the Phase 3 trial and the potential for significant clinical benefits [10][124] Other Important Information - The company received a $1.7 million grant from the Michael J. Fox Foundation for Parkinson's Research to support research on GPNMB [34] - A virtual educational event is planned for Q2 2025 to share additional preclinical data on the ABC platform [35] Q&A Session Summary Question: Regarding the INFRONT study and patient enrollment - Management confirmed that they intentionally targeted early symptomatic populations and capped enrollment for more progressed patients to enhance efficacy [44][45] Question: On AL101 and its relation to INFRONT-3 - Management indicated that there is no significant read-through from the TREM2 trial to AL101 due to differing mechanisms [57][66] Question: About the ABC platform and its differentiation - Management highlighted the versatility and tunability of the ABC platform compared to competitors, emphasizing its potential for optimized efficacy and safety [75][78] Question: On siRNA versus ASOs - Management noted that siRNA may offer better on-target activity and fewer side effects compared to ASOs, with ongoing testing to determine efficacy [82] Question: Regarding the INFRONT-3 trial design and patient enrichment - Management explained the challenges in patient enrichment and the decision to focus on symptomatic patients based on observed progression rates [120][121]

Financial Status & Pipeline - Alector had $413.4 million in cash, cash equivalents, and marketable securities as of December 31, 2024, providing a runway through 2026[17, 18] - Alector is targeting 2 INDs (Investigational New Drug) in 2026[9] - Alector's IP portfolio contains 60+ patent families, including 128 issued patents and >500 pending patent applications[16] PGRN Programs & Clinical Trials - Pivotal Phase 3 data for Latozinemab in FTD (frontotemporal dementia) is expected by Q4 2025[9, 49, 68] - Phase 2 enrollment for AL101 in AD (Alzheimer's disease) is expected to be completed by mid-2025[9, 57, 68] - In the INFRONT-2 trial, Latozinemab treatment decreased Glial Fibrillary Acidic Protein (GFAP) levels towards the range seen in asymptomatic carriers of FTD-GRN mutation[35] - Preliminary data from INFRONT-2 suggests Latozinemab may slow disease progression in FTD-GRN participants by approximately 48% compared to matched historical controls, representing a 3.1 point change in CDR® plus NACC FTLD-SB[45] Collaboration with GSK - Alector has a profit-sharing collaboration with GSK for multiple PGRN product candidates[9] - The collaboration includes $700 million upfront payments and $1.5 billion+ in potential milestone payments[68] ABC Technology - Alector Brain Carrier (ABC) technology platform is designed to enhance the delivery of biologics across the blood-brain barrier (BBB)[9, 13] - The ABC technology aims to improve outcomes while reducing costs by enhancing delivery of therapeutics to achieve deeper brain penetration at lower doses[13]

Financial Performance - The company incurred net losses of $133.3 million, $130.4 million, and $119.0 million for the years ended December 31, 2022, 2023, and 2024, respectively, with an accumulated deficit of $829.1 million as of December 31, 2024[230]. - The company has no products approved for commercial sale and has not generated any revenue from product sales to date[227]. - The company anticipates needing substantial additional financing to complete the development and commercialization of its product candidates[240]. - The company has a limited operating history and no completed pivotal clinical trials, making future success uncertain[228]. - The company has invested significantly in the development of its product candidates, including the ABC technology platform, which requires substantial capital investment[246]. - The company has entered into a loan agreement allowing access to up to $50 million, with an initial tranche of $25 million available through June 30, 2026[249]. - The company may face challenges in raising additional capital due to market volatility and instability, which could impact its ability to fund research and development programs[244]. Research and Development - The company plans to continue its research and development activities, which are expected to incur significant expenses and operating losses for the foreseeable future[234]. - The company has terminated clinical development for three product candidates, including AL002 and AL044, due to failure to meet primary endpoints in trials[239]. - The company is currently developing two product candidates, latozinemab in Phase 3 and AL101 in Phase 2 clinical trials, with no guarantee of success in these trials[255]. - The company has inactivated the IND application for AL101 in FTD, focusing on larger indications such as Alzheimer's disease and Parkinson's disease[227]. - The company’s drug development strategy includes seeking regulatory approval for indications where it can quickly generate proof-of-concept data, but this requires substantial resources[263]. - The company may need to prioritize certain product candidates due to limited resources, which could lead to missed opportunities in potentially more profitable areas[246]. - The company’s reliance on genetic screening and biomarkers may necessitate the development of companion diagnostics, impacting product development costs and timelines[247]. Regulatory and Approval Risks - The company’s ability to obtain regulatory approval for its product candidates is uncertain, and failure to do so could adversely affect its business viability[256]. - Clinical trials are expensive and time-consuming, with potential delays that could impair revenue generation and product commercialization[267]. - The neurodegenerative disease field is characterized by high failure rates in clinical trials, with many candidates never receiving regulatory approval[280]. - Regulatory approval processes are lengthy and unpredictable, with no guarantee that any product candidates will receive approval, significantly impacting revenue generation[314]. - The acceptance of clinical trial data from studies conducted outside the United States by regulatory authorities is uncertain, which could necessitate additional trials and delay commercialization[325]. - Changes in FDA leadership and policies under new administrations may lead to further regulatory uncertainties and delays in the approval process[319]. - The company may experience delays in regulatory approvals due to external factors such as government shutdowns or budget constraints affecting the FDA[315]. Competition and Market Challenges - The company faces significant competition in the neurodegenerative field, with potential competitors achieving regulatory approval before it does[284]. - The company faces risks related to the commercialization of its product candidates, including competition and market acceptance challenges[258]. - Competitors may obtain regulatory approvals more rapidly, establishing a strong market position before the company can enter the market[287]. - The company’s future pipeline opportunities may be reduced if it fails to successfully develop and apply its proprietary ABC technology[261]. - There are currently limited approved therapeutic options for patients with FTD, Alzheimer's disease, and Parkinson's disease, highlighting the need for new treatments[265]. Manufacturing and Supply Chain Risks - The complexity of manufacturing product candidates poses risks, including potential delays in clinical trials and regulatory approvals[289]. - The company relies on third-party manufacturers for the production of materials for preclinical studies, clinical trials, and commercialization, which increases the risk of supply shortages and cost issues[381]. - The company faces competition for access to limited manufacturing facilities, which may affect its ability to produce medicines[383]. - Any performance failures by third-party manufacturers could delay clinical development or marketing approval, leading to increased costs and delays[384]. - The company's dependence on third-party suppliers for key raw materials poses risks related to supply chain disruptions and geopolitical events[386]. Intellectual Property and Compliance - The company is actively pursuing patent protection for its product candidates, but there is no guarantee that these applications will result in granted patents[389]. - Changes in patent laws or interpretations could adversely affect the company's ability to protect its intellectual property[390]. - The company may face challenges in protecting its intellectual property rights globally, as foreign laws may not provide the same level of protection as U.S. laws[410]. - The company enters into non-disclosure and confidentiality agreements to protect its trade secrets, but there is no guarantee that all parties will comply, which could lead to breaches and loss of competitive position[424]. - The company is subject to various obligations under collaboration agreements, and failure to meet these could result in loss of rights to develop and commercialize products[407]. Healthcare Regulations and Legislative Risks - Legislative measures, such as the Inflation Reduction Act of 2022, may significantly impact the pharmaceutical industry, including price negotiations for high-cost drugs[346]. - The elimination of the statutory cap on Medicaid Drug Rebate Program rebates may require pharmaceutical manufacturers to pay more in rebates than they receive from sales[346]. - Ongoing healthcare reforms may lead to reductions in Medicare funding and more stringent coverage criteria, impacting reimbursement rates[352]. - The company faces uncertainty regarding the future of federal and state healthcare legislation that could affect revenue and operational costs[351]. - State-level regulations are increasingly imposing price controls and transparency measures, potentially increasing compliance costs for the company[349].

Financial Performance - Alector reported collaboration revenue of $54.2 million for Q4 2024, up from $15.2 million in Q4 2023, and total collaboration revenue for 2024 reached $100.6 million, compared to $97.1 million in 2023[10]. - Alector's net loss for Q4 2024 was $2.1 million, or $0.02 per share, significantly improved from a net loss of $41.4 million, or $0.49 per share, in Q4 2023; for the full year, the net loss was $119.0 million, or $1.23 per share, compared to $130.4 million, or $1.56 per share, in 2023[13]. - The net loss for the three months ended December 31, 2024, was $2.07 million, compared to a net loss of $41.43 million in the same period of 2023, showing an improvement of 95%[22]. - Net loss per share for the twelve months ended December 31, 2024, was $1.23, down from $1.56 in 2023, reflecting a reduction of 21%[22]. - The net loss before income tax for the twelve months ended December 31, 2024, was $118.92 million, down from $125.18 million in 2023, indicating a reduction of 5%[22]. - Income tax expense for the three months ended December 31, 2024, was $48, significantly lower than $1.67 million in the same period of 2023, reflecting a decrease of 97%[22]. Research and Development - Total research and development expenses for Q4 2024 were $46.5 million, a slight decrease from $47.7 million in Q4 2023, while total R&D expenses for the year were $185.9 million, down from $192.1 million in 2023[11]. - Research and development expenses for the twelve months ended December 31, 2024, totaled $185.94 million, a decrease from $192.12 million in 2023, representing a decline of 3%[22]. - Alector plans to complete enrollment in the PROGRESS-AD Phase 2 trial of AL101/GSK4527226 by mid-2025, which is evaluating early Alzheimer's disease[2]. - Alector is advancing two proprietary programs, ADP037-ABC targeting amyloid beta and ADP050-ABC for GCase replacement therapy, with plans to enter the clinic in 2026[3]. - The pivotal INFRONT-3 Phase 3 trial of latozinemab is ongoing, with topline data expected by Q4 2025, targeting frontotemporal dementia with a granulin gene mutation[6]. - Alector received a $1.7 million grant from The Michael J. Fox Foundation for collaborative research on GPNMB, a target for Parkinson's disease[7]. Financial Position - As of December 31, 2024, Alector had cash, cash equivalents, and investments totaling $413.4 million, expected to fund operations through 2026[14]. - Alector's total assets decreased to $468.3 million as of December 31, 2024, from $621.8 million in 2023, while total liabilities decreased to $341.5 million from $487.7 million[20]. Operating Expenses - Total operating expenses for the twelve months ended December 31, 2024, were $245.56 million, slightly down from $248.80 million in 2023, indicating a decrease of 1%[22]. - General and administrative expenses for the three months ended December 31, 2024, were $15.03 million, slightly up from $14.92 million in the same period of 2023, indicating an increase of 1%[22]. - Other income for the twelve months ended December 31, 2024, was $26.08 million, compared to $26.56 million in 2023, showing a decrease of 2%[22]. Future Projections - Alector anticipates collaboration revenue for 2025 to be between $5 million and $15 million, with R&D expenses projected between $175 million and $185 million, and G&A expenses expected to be between $55 million and $65 million[14].

PART I. FINANCIAL INFORMATION [Item 1. Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements) Alector, Inc.'s unaudited condensed consolidated financial statements for Q3 and YTD September 2024 are presented, showing a $117.0 million net loss for the nine-month period and $71.1 million from a January 2024 public offering Condensed Consolidated Balance Sheet Highlights (in thousands) | Metric | September 30, 2024 (in thousands) | December 31, 2023 (in thousands) | | :--- | :--- | :--- | | Cash, cash equivalents, and marketable securities | $457,202 | $548,861 | | Total Assets | $516,023 | $621,827 | | Total Liabilities | $397,090 | $487,669 | | Total Stockholders' Equity | $118,933 | $134,158 | Condensed Consolidated Statement of Operations Highlights (in thousands) | Metric | Three Months Ended Sep 30, 2024 (in thousands) | Three Months Ended Sep 30, 2023 (in thousands) | Nine Months Ended Sep 30, 2024 (in thousands) | Nine Months Ended Sep 30, 2023 (in thousands) | | :--- | :--- | :--- | :--- | :--- | | Collaboration Revenue | $15,342 | $9,109 | $46,318 | $81,872 | | Research and Development | $47,998 | $46,328 | $139,479 | $144,392 | | Net Loss | $(42,220) | $(44,475) | $(116,975) | $(88,957) | | Net Loss Per Share | $(0.43) | $(0.53) | $(1.22) | $(1.07) | Condensed Consolidated Statement of Cash Flows Highlights (in thousands) | Metric | Nine Months Ended Sep 30, 2024 (in thousands) | Nine Months Ended Sep 30, 2023 (in thousands) | | :--- | :--- | :--- | | Net cash used in operating activities | $(174,877) | $(138,092) | | Net cash provided by investing activities | $65,729 | $83,847 | | Net cash provided by financing activities | $71,752 | $1,960 | - In January 2024, the company completed a public offering, issuing 10,869,566 shares of common stock which resulted in aggregate net proceeds of **$71.1 million**[21](index=21&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=17&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's financial condition and operations, highlighting progress in clinical programs for FTD and Alzheimer's, supported by collaboration revenues and a cash runway through 2026 - The company is focusing its development resources on key clinical candidates: **latozinemab** for frontotemporal dementia (FTD), and **AL002** and **AL101** for Alzheimer's disease (AD)[46](index=46&type=chunk) - Key clinical milestones achieved include target enrollment in the pivotal **Phase 3 INFRONT-3 trial for latozinemab**, **FDA Breakthrough Therapy Designation for latozinemab**, and the first participant dosed in the **PROGRESS-AD Phase 2 trial for AL101**[46](index=46&type=chunk) - As of September 30, 2024, the company had **$457.2 million** in cash, cash equivalents, and marketable securities, which is anticipated to provide a financial runway **through 2026**[48](index=48&type=chunk)[72](index=72&type=chunk) Comparison of Results of Operations (in thousands) | Metric | Three Months Ended Sep 30, 2024 (in thousands) | Three Months Ended Sep 30, 2023 (in thousands) | Nine Months Ended Sep 30, 2024 (in thousands) | Nine Months Ended Sep 30, 2023 (in thousands) | | :--- | :--- | :--- | :--- | :--- | | Collaboration Revenue | $15,342 | $9,109 | $46,318 | $81,872 | | R&D Expenses | $47,998 | $46,328 | $139,479 | $144,392 | | G&A Expenses | $15,778 | $13,364 | $44,587 | $41,767 | | Net Loss | $(42,220) | $(44,475) | $(116,975) | $(88,957) | [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=26&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risk is interest rate sensitivity on its $457.2 million investment portfolio, with foreign currency risk deemed minimal due to U.S. dollar-denominated expenses - The company's primary market risk is **interest rate sensitivity**. An immediate **100 basis point change** in interest rates would cause a change in the fair value of its investment portfolio of approximately **$2.2 million** as of September 30, 2024[82](index=82&type=chunk) - Foreign currency risk is **not considered material** as expenses are generally denominated in **U.S. dollars**. A 10% change in exchange rates would **not have a material effect** on financial results[83](index=83&type=chunk) [Item 4. Controls and Procedures](index=27&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of September 30, 2024, with no material changes to internal control over financial reporting during the quarter - Based on an evaluation as of September 30, 2024, the Principal Executive Officer and Principal Financial and Accounting Officer concluded that the company's disclosure controls and procedures were **effective at a reasonable assurance level**[85](index=85&type=chunk) - **No changes in internal control over financial reporting** occurred during the quarter ended September 30, 2024, that have materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[86](index=86&type=chunk) PART II. OTHER INFORMATION [Item 1. Legal Proceedings](index=28&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently a party to any legal proceedings expected to have a material adverse effect on its business - As of the filing date, the company is **not a party to any litigation or legal proceedings** that are expected to have a **material adverse effect** on its business[87](index=87&type=chunk) [Item 1A. Risk Factors](index=28&type=section&id=Item%201A.%20Risk%20Factors) This section outlines significant risks including limited operating history, substantial net losses, high uncertainty in neurodegenerative drug development, reliance on third parties, and the need for additional financing - The company has a **limited operating history**, **no approved products**, and has incurred **significant net losses** each year, with an **accumulated deficit of $827.1 million** as of September 30, 2024[91](index=91&type=chunk)[92](index=92&type=chunk)[93](index=93&type=chunk) - The business is **heavily dependent on the success of its product candidates**, which are in various stages of development. Drug development is **inherently risky**, particularly in the field of neurodegenerative diseases, which has seen **limited success**[96](index=96&type=chunk)[101](index=101&type=chunk)[106](index=106&type=chunk) - The company will need to obtain **substantial additional financing** to complete development and commercialization. Failure to raise capital could force **delays, reductions, or termination of its programs**[98](index=98&type=chunk) - The company **depends on collaborations with third parties** like GSK and AbbVie for development and commercialization, and these collaborations pose risks such as **potential termination or underperformance by partners**[162](index=162&type=chunk) - Clinical trials may face **substantial delays, enrollment difficulties, or fail to demonstrate safety and efficacy**. For example, **treatment-emergent MRI findings resembling ARIA** have been observed in the INVOKE-2 Phase 2 clinical trial[107](index=107&type=chunk)[111](index=111&type=chunk)[114](index=114&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=78&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reports no unregistered sales of equity securities during the period - **None**[233](index=233&type=chunk) [Item 5. Other Information](index=78&type=section&id=Item%205.%20Other%20Information) This section discloses the termination and adoption of new Rule 10b5-1 trading plans by the CFO for the potential sale of up to 84,357 shares of common stock - On September 12, 2024, CFO Marc Grasso **terminated a Rule 10b5-1 trading plan** adopted in August 2023[234](index=234&type=chunk) - On September 13, 2024, CFO Marc Grasso **adopted a new Rule 10b5-1 trading plan** for the exercise of options and sale of **up to 84,357 shares of common stock**, which will expire on September 13, 2025[234](index=234&type=chunk) [Item 6. Exhibits](index=78&type=section&id=Item%206.%20Exhibits) This section provides an index of exhibits filed with the Form 10-Q, including certifications from the Principal Executive Officer and Principal Financial Officer - The report includes **certifications from the Principal Executive Officer and Principal Financial Officer** pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act of 2002[235](index=235&type=chunk)[237](index=237&type=chunk)

[Executive Summary & Business Highlights](index=1&type=section&id=Executive%20Summary%20%26%20Business%20Highlights) Alector reported strong Q3 2024 financial results, a robust cash position, and key updates on its TREM2 and Progranulin clinical programs [Q3 2024 Overview](index=1&type=section&id=Q3%202024%20Overview) Alector reported strong Q3 2024 results, maintaining a **$457.2 million** cash position through 2026, and updated on key clinical programs AL002 and latozinemab - Alector's cash, cash equivalents, and investments totaled **$457.2 million** as of September 30, 2024, providing a financial runway through **2026**[1](index=1&type=chunk)[13](index=13&type=chunk) - Data from the INVOKE-2 Phase 2 trial, evaluating TREM2 agonist candidate AL002 in early Alzheimer's disease, is on track for release in **2024**[1](index=1&type=chunk)[2](index=2&type=chunk) - Participant baseline characteristics in the pivotal INFRONT-3 Phase 3 trial for latozinemab in FTD-GRN suggest a representative study population[1](index=1&type=chunk)[2](index=2&type=chunk) [CEO & R&D Head Commentary](index=1&type=section&id=CEO%20%26%20R%26D%20Head%20Commentary) CEO and R&D Head highlighted significant pipeline progress, including AL002's potential, INFRONT-3 patient data, PROGRESS-AD enrollment, and ABC technology advancements - AL002, the most advanced TREM2 candidate for early Alzheimer's disease, is expected to report INVOKE-2 Phase 2 trial data in **2024**, with potential for potent and durable therapeutic benefits[2](index=2&type=chunk) - The INFRONT-3 Phase 3 clinical trial for latozinemab in FTD-GRN has reported patient baseline characteristics suggesting a representative study population, with top-line data expected in **late 2025/early 2026**[2](index=2&type=chunk) - PROGRESS-AD, the Phase 2 trial of AL101/GSK4527226 in early Alzheimer's disease, has reached over **one-third** of its target enrollment[2](index=2&type=chunk) - Alector is actively advancing its proprietary Alector Brain Carrier (ABC) technology platform to improve the delivery of therapeutics to the brain for neurodegenerative diseases[2](index=2&type=chunk) [Recent Clinical Updates](index=2&type=section&id=Recent%20Clinical%20Updates) Alector provided comprehensive updates on its immuno-neurology pipeline, including TREM2 and Progranulin programs, and Alector Brain Carrier technology advancements [Immuno-Neurology Portfolio](index=2&type=section&id=Immuno-Neurology%20Portfolio) Alector updated its immuno-neurology pipeline, covering the TREM2 program (AL002) and Progranulin programs (latozinemab and AL101/GSK4527226) for neurodegenerative diseases [TREM2 Program (AL002)](index=2&type=section&id=TREM2%20Program%20(AL002)) The AL002 Phase 2 INVOKE-2 trial for early Alzheimer's disease is on track for 2024 results, with AbbVie holding a **$250 million** option for global rights - Results from the INVOKE-2 Phase 2 clinical trial of AL002 for early Alzheimer's disease are expected in **2024**[3](index=3&type=chunk) - **98%** of eligible participants who completed the planned treatment period of INVOKE-2 have elected to participate in the long-term extension (LTE) study[4](index=4&type=chunk) - A manuscript published in **October 2024** detailed preclinical and INVOKE-1 Phase 1 study results, showing AL002 engaged TREM2 and induced pharmacodynamic biomarker changes associated with microglial proliferation, survival, and phagocytic activity[5](index=5&type=chunk) - AbbVie has an exclusive option to globally develop and commercialize AL002, with a **$250 million** payment to Alector upon exercise[6](index=6&type=chunk) [Progranulin Programs (latozinemab (AL001) and AL101/GSK4527226)](index=2&type=section&id=Progranulin%20Programs%20(latozinemab%20(AL001)%20and%20AL101%2FGSK4527226)) The pivotal INFRONT-3 Phase 3 trial for latozinemab in FTD-GRN is on track for late 2025/early 2026 data, with AL101/GSK4527226's PROGRESS-AD trial progressing - The pivotal INFRONT-3 Phase 3 clinical trial of latozinemab for FTD-GRN is ongoing and on track, with enrollment completed in **October 2023** and a treatment duration of **96 weeks**[6](index=6&type=chunk) - Top-line data readout for INFRONT-3 is approaching in **late 2025/early 2026**[2](index=2&type=chunk) - Baseline characteristics of symptomatic INFRONT-3 participants were representative of the broader FTD-GRN registry population[7](index=7&type=chunk) - PROGRESS-AD, a Phase 2 clinical study evaluating AL101/GSK4527226 in early AD, has reached more than **one-third** of its target enrollment of **282 participants**[8](index=8&type=chunk) [Early Research Pipeline](index=3&type=section&id=Early%20Research%20Pipeline) Alector is advancing its proprietary Alector Brain Carrier (ABC) technology to optimize therapeutic delivery to the brain for next-generation immuno-neurology treatments - Alector continues to advance its Alector Brain Carrier (ABC), a proprietary, versatile blood-brain barrier technology platform[9](index=9&type=chunk) - The ABC technology platform enables customization of affinity, valency, and format to optimize effector function and half-life in preclinical models, aiming to improve delivery of therapeutics to the brain[9](index=9&type=chunk) [Third Quarter 2024 Financial Results](index=3&type=section&id=Third%20Quarter%202024%20Financial%20Results) Alector reported Q3 2024 financial results, detailing changes in collaboration revenue, operating expenses, net loss, and current cash position [Financial Performance Summary](index=3&type=section&id=Financial%20Performance%20Summary) Alector's Q3 2024 saw increased collaboration revenue, higher operating expenses, a reduced net loss, and a strong cash position despite a facility transition impairment [Collaboration Revenue](index=3&type=section&id=Collaboration%20Revenue) Collaboration revenue for Q3 2024 significantly increased year-over-year, driven by higher revenue recognition from the AL002 program | Metric | Q3 2024 (USD thousands) | Q3 2023 (USD thousands) | Change (YoY) | | :----- | :---------------------- | :---------------------- | :----------- | | Collaboration revenue | $15,342 | $9,109 | +$6,233 (+68.4%) | [Research and Development Expenses](index=3&type=section&id=Research%20and%20Development%20Expenses) Total R&D expenses for Q3 2024 modestly increased, driven by higher spending on AL101 programs and PROGRESS-AD Phase 2 clinical trial initiation | Metric | Q3 2024 (USD thousands) | Q3 2023 (USD thousands) | Change (YoY) | | :----- | :---------------------- | :---------------------- | :----------- | | Research and development | $47,998 | $46,328 | +$1,670 (+3.6%) | [General and Administrative Expenses](index=3&type=section&id=General%20and%20Administrative%20Expenses) G&A expenses increased in Q3 2024, primarily due to an impairment charge from a facility transition to the South San Francisco headquarters | Metric | Q3 2024 (USD thousands) | Q3 2023 (USD thousands) | Change (YoY) | | :----- | :---------------------- | :---------------------- | :----------- | | General and administrative | $15,778 | $13,364 | +$2,414 (+18.1%) | [Net Loss and EPS](index=3&type=section&id=Net%20Loss%20and%20EPS) Alector reported a reduced net loss and improved net loss per share for Q3 2024 compared to the prior year | Metric | Q3 2024 (USD million) | Q3 2023 (USD million) | Change (YoY) | | :----- | :-------------------- | :-------------------- | :----------- | | Net loss | $(42.2) | $(44.5) | -$2.3 (-5.2%) | | Net loss per share (USD) | $(0.43) | $(0.53) | -$0.10 (-18.9%) | [Cash Position](index=3&type=section&id=Cash%20Position) As of September 30, 2024, Alector maintained a strong cash position of **$457.2 million**, projected to fund operations through 2026 | Metric | As of Sep 30, 2024 (USD million) | As of Dec 31, 2023 (USD million) | Change (USD million) | | :----- | :------------------------------- | :------------------------------- | :------------------- | | Cash, cash equivalents, and investments | $457.2 | $548.9 | -$91.7 | [2024 Financial Guidance](index=4&type=section&id=2024%20Financial%20Guidance) Alector provided its full-year 2024 financial guidance, including projections for collaboration revenue and operating expenses [Full-Year 2024 Guidance](index=4&type=section&id=Full-Year%202024%20Guidance) Alector reiterated its full-year 2024 financial guidance, projecting collaboration revenue between **$60 million and $70 million** and total operating expenses between **$270 million and $290 million** | Metric | 2024 Guidance Range (USD million) | | :----- | :-------------------------------- | | Collaboration revenue | $60 - $70 | | Total R&D expenses | $210 - $220 | | Total G&A expenses | $60 - $70 | [Company Information](index=4&type=section&id=Company%20Information) This section provides an overview of Alector's immuno-neurology mission and includes standard forward-looking statements [About Alector](index=4&type=section&id=About%20Alector) Alector is a clinical-stage biotechnology company pioneering immuno-neurology, targeting immune dysfunction as a root cause of neurodegenerative diseases - Alector is a clinical-stage biotechnology company pioneering immuno-neurology for neurodegenerative diseases[15](index=15&type=chunk) - Its therapeutic approach targets immune dysfunction as a root cause of degenerative brain disorders[15](index=15&type=chunk) - Alector's product candidates are supported by biomarkers and seek to treat indications including Alzheimer's disease and genetically defined frontotemporal dementia patient populations[15](index=15&type=chunk) [Forward-Looking Statements](index=4&type=section&id=Forward-Looking%20Statements) This section contains standard forward-looking statements regarding Alector's business, product candidates, and financial guidance, subject to risks in SEC filings - The press release contains forward-looking statements regarding business plans, product candidates, clinical trials, and financial guidance[16](index=16&type=chunk) - Such statements are subject to numerous risks and uncertainties, including those set forth in Alector's Quarterly Report on Form 10-Q filed with the SEC[16](index=16&type=chunk) - Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law[16](index=16&type=chunk) [Financial Statements](index=5&type=section&id=Financial%20Statements) This section presents Alector's selected consolidated balance sheet and statement of operations data for the reported periods [Selected Consolidated Balance Sheet Data](index=5&type=section&id=Selected%20Consolidated%20Balance%20Sheet%20Data) Alector's consolidated balance sheet data shows a decrease across cash, total assets, liabilities, and stockholders' equity from December 31, 2023, to September 30, 2024 | Metric (USD thousands) | Sep 30, 2024 (USD thousands) | Dec 31, 2023 (USD thousands) | | :-------------------- | :--------------------------- | :--------------------------- | | Cash, cash equivalents, and marketable securities | $457,202 | $548,861 | | Total assets | $516,023 | $621,827 | | Total current liabilities (excluding deferred revenue) | $87,098 | $94,973 | | Deferred revenue (including current portion) | $248,202 | $293,820 | | Total liabilities | $397,090 | $487,669 | | Total stockholders' equity | $118,933 | $134,158 | [Consolidated Statement of Operations Data](index=5&type=section&id=Consolidated%20Statement%20of%20Operations%20Data) The consolidated statement of operations data for Q3 2024 shows increased collaboration revenue and reduced net loss, while the nine-month period reflects decreased revenue and increased net loss | Metric (USD thousands, except per share) | Q3 2024 (USD thousands) | Q3 2023 (USD thousands) | 9 Months Ended Sep 30, 2024 (USD thousands) | 9 Months Ended Sep 30, 2023 (USD thousands) | | :------------------------------------------ | :---------------------- | :---------------------- | :------------------------------------------ | :------------------------------------------ | | Collaboration revenue | $15,342 | $9,109 | $46,318 | $81,872 | | Research and development | $47,998 | $46,328 | $139,479 | $144,392 | | General and administrative | $15,778 | $13,364 | $44,587 | $41,767 | | Total operating expenses | $63,776 | $59,692 | $184,066 | $186,159 | | Loss from operations | $(48,434) | $(50,583) | $(137,748) | $(104,287) | | Other income, net | $6,214 | $7,360 | $20,853 | $18,876 | | Net loss before income tax | $(42,220) | $(43,223) | $(116,895) | $(85,411) | | Income tax expense | — | $1,252 | $80 | $3,546 | | Net loss | $(42,220) | $(44,475) | $(116,975) | $(88,957) | | Net loss per share, basic and diluted (USD) | $(0.43) | $(0.53) | $(1.22) | $(1.07) | | Shares used in computing net loss per share basic and diluted | 97,519,595 | 83,927,961 | 96,007,105 | 83,513,954 | [Contacts](index=6&type=section&id=Contacts) This section provides essential contact information for Alector's corporate, media, and investor relations [Alector Contacts](index=6&type=section&id=Alector%20Contacts) This section provides contact information for Alector's corporate communications, media relations, and investor relations - Contact information for Alector (Katie Hogan), media (Dan Budwick at 1AB), and investors (Laura Perry at Argot Partners) is provided[19](index=19&type=chunk)